Skip to content
Let's talk ↗

INSIGHTS

42 CFR Part 2 and Marketing Consent: What Rehab Marketers Must Know

F7viQcWRvAS

A former patient’s success story can help someone feel less alone. But if your team shares that story without the right permission, an effort to build trust can create a serious privacy problem.

For rehab marketers, 42 CFR Part 2 marketing consent calls for more than a general HIPAA release or a casual “yes.” Before using patient information in a testimonial, email, ad audience or follow-up campaign, you need to understand what information is protected, what the permission covers and who will receive it.

This article is educational, not legal advice. Ask qualified legal or compliance counsel to review your specific program, consent forms, marketing platforms and state-law obligations.

Table of Contents

What is 42 CFR Part 2?

42 CFR Part 2 is a federal rule that protects the confidentiality of substance use disorder (SUD) patient records held by qualifying SUD programs. In general, the rule restricts when covered records can be used or disclosed, especially when a person could be identified as having sought or received SUD services.

Why the additional protection? People may worry that disclosure of SUD treatment information could lead to stigma, discrimination or other harm. Part 2 aims to protect privacy and support confidence in seeking care. It does not apply to every provider or every record simply because substance use is mentioned; whether a program and its records fall within Part 2 depends on the rules and the facts. Start with SAMHSA’s Part 2 resources and the current Part 2 regulations, then have counsel confirm how they apply to your organization.

Part 2 and HIPAA: What’s different?

HIPAA applies to covered entities and business associates and sets rules for protecting protected health information (PHI). Part 2 can apply to records from a qualifying SUD program, including information that identifies someone as having applied for or received SUD diagnosis or treatment.

If both rules apply, it’s not safe to assume a routine HIPAA form covers every Part 2 use. Part 2 has its own consent requirements and restrictions. A disclosure that may be permitted under HIPAA alone may still need a valid Part 2 consent or another applicable legal basis.

That matters in marketing, where patient identity and treatment history can be especially sensitive. It also matters when your center works with an outside agency, call center or technology vendor. Have counsel assess what information is being handled, the vendor’s role, required agreements and safeguards, and whether the planned use is allowed.

What changed in the 2024 final rule?

HHS published its final rule on February 16, 2024. It took effect April 16, 2024, with a compliance deadline of February 16, 2026. That compliance date has passed. The rule aligned some Part 2 requirements more closely with HIPAA and introduced a single-consent option for certain future treatment, payment and health care operations (TPO) uses and disclosures. See the HHS Part 2 overview and 2024 final rule.

The important marketing distinction: a TPO consent is not a blanket marketing permission. Marketing is a separate purpose. A consent that permits records to be used for TPO does not, by itself, authorize using them to promote your facility.

The final rule also established HIPAA-aligned enforcement provisions. HHS announced that its Office for Civil Rights would begin accepting Part 2 complaints and breach notifications on February 16, 2026. That makes a current review of consent and data-handling practices a practical priority, not just a paperwork exercise. HHS OCR’s enforcement announcement has further details.

Does marketing need its own consent?

Often, if your marketing plan uses or discloses identifiable Part 2 information, you should expect to need specific written consent for that marketing purpose, and, where HIPAA applies, a HIPAA-compliant authorization as well. HIPAA generally requires an individual’s written authorization for marketing uses of PHI, subject to limited exceptions. See HHS guidance on HIPAA and marketing.

Part 2 consent rules require details such as who may disclose the information, what information is covered, the purpose, the recipient or recipient class, an expiration date or event, and how consent may be revoked. The requirements are set out in 42 CFR § 2.31. A general intake form or broad release may not clearly cover a marketing use. Ask counsel to review the form and the actual campaign, not just its title.

Testimonials and patient stories

A public testimonial can reveal that someone received care, even if you omit a diagnosis. Before publishing a name, image, video, quote or identifiable story, get the right written permission for the particular use and channel. Make sure the person understands what will be shared, where it may appear and how long the permission lasts. A release for a website photo should not automatically be treated as permission for paid ads, email campaigns or social posts.

Also, don’t confirm someone’s patient status in a reply to an online review. A well-meaning “We’re so glad you recovered with us” can disclose what the reviewer’s comment alone did not. Develop a response process with compliance counsel.

Marketing activity and consent: A practical guide

The table below is an operational starting point, not a legal determination. The answer may vary with the data, program, platform and applicable state law.

Marketing activity Consent considerations
General educational content or a broad, untargeted ad Usually does not rely on patient records. Keep patient-identifiable information out of the creative and audience data.
Responding to a person who asks for a call Use the contact information to answer the request as described. Ask counsel to distinguish requested follow-up from ongoing promotional messages.
Promotional email to a patient or former patient Obtain and document appropriate marketing permission for any Part 2 information used or disclosed; assess HIPAA authorization and email-marketing rules too.
Patient testimonial, photo or video Obtain specific written permission for the information and uses planned. Don’t assume a general treatment consent is enough.
Retargeting based on a patient list, intake record or treatment activity Pause until counsel reviews the data flow, audience creation, platform and required consent. A list upload or tracking tool can disclose sensitive information.
Replies to reviews or social comments Don’t confirm or imply that the commenter is a patient. Use a neutral, privacy-protective response.

Retargeting, email lists and follow-up: What should you check?

Digital advertising can turn routine site activity into a privacy question. A tracking pixel, audience upload or analytics integration may send information to a third party. If identifiers are connected to a treatment inquiry or activity on an SUD service page, counsel should assess whether the data could identify someone or reveal a connection to care. Don’t assume a cookie banner or vendor contract alone authorizes the disclosure.

For email, separate people who asked for a response from people who agreed to receive ongoing promotional content. Keep the source and scope of each permission, record opt-outs and revocations, and ensure suppression lists are honored. Ask counsel whether the data is subject to Part 2, HIPAA, state privacy laws and other applicable rules before uploading it to an ad or email platform.

Email and audience-list illustration showing a privacy boundary

Guardrails for marketing and admissions teams

A practical workflow helps protect privacy without leaving your team guessing:

  1. Map the data. List what comes from web forms, calls, admissions systems, the EHR, reviews and vendors. Identify where it goes.
  2. Separate permission by purpose. A request for a callback is not automatically permission for an ongoing promotional email series or a testimonial.
  3. Use approved forms and scripts. Train staff to explain optional marketing permissions plainly and avoid pressuring people to agree.
  4. Track consent and revocation. Store the form, scope, date, expiration and any revocation in a place marketing and admissions can check before use.
  5. Review vendors and tools. Have counsel assess pixels, analytics, CRM integrations, list uploads and the agreements or safeguards required.
  6. Set a stop-and-ask rule. If staff are unsure whether a contact is a patient or whether information can be shared, pause the campaign and ask the privacy lead.

A real-world example: someone fills out a form asking about residential treatment and checks a box requesting a call. That request gives admissions a clear reason to respond. It does not automatically settle whether the person can be added to a long-term promotional email list, used in an ad audience or asked for a public recovery story.

Admissions team reviewing a privacy checklist beside a secure file icon

Your website and campaigns can still explain your services clearly without turning patient records into marketing assets. Ads Up Marketing supports rehab and behavioral health organizations with content creation, website design and Google Ads. We also cover content monitoring and ethical boundaries in addiction treatment marketing. Bring your privacy or compliance counsel into the discussion before a campaign launches.

If you’re reviewing your digital marketing setup and want to talk through privacy-conscious ways to reach prospective clients, contact Ads Up Marketing or call 305-539-7114. We can help you assess your marketing workflow; your qualified counsel should guide legal decisions.

Frequently asked questions

Does a HIPAA consent form automatically cover Part 2 marketing?

No. HIPAA and Part 2 have distinct requirements. A HIPAA form or TPO consent should not be treated as automatic permission for marketing use of Part 2 information. Have qualified counsel review the specific form, data and proposed use.

Can a rehab center use a patient testimonial if the person agrees verbally?

Do not rely on verbal agreement for a Part 2 marketing disclosure. Written consent requirements may apply, and the permission should clearly describe the information, purpose, recipient and intended uses. Ask counsel to review the consent and testimonial workflow before publication.

Can a rehab center retarget website visitors?

It depends on what the tracking tools collect, how the data is connected to identifiable people, and where it is sent. Have counsel review the pixels, analytics, audience settings and disclosures before using retargeting in a treatment context.

When did the 2024 Part 2 rule take effect?

The final rule took effect April 16, 2024, and required compliance by February 16, 2026. As of October 2026, that compliance date has passed. Review the HHS Part 2 resources and consult counsel about your program’s obligations.

Educational information only; not legal advice. Consult qualified legal or compliance counsel about your organization’s obligations.